9/19/2013

Aerie Pharmaceuticals, a Bedminster, N.J.-based developer of eye disease treatments, could bring in as much as $57.5 million in an initial public offering. The company plans to use the money to create a sales force and advance its experimental glaucoma drug AR-13324 through a Phase III trial and the drug PG324 through a midstage trial.

Related Summaries